Technical Analysis for 0H7R - Abeona Therapeutics Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.57 | 10.57% | 0.34 |
0H7R closed up 10.57 percent on Monday, April 29, 2024, on 7.57 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Buy Signal | Bullish | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 180 Bearish Setup | Bearish Swing Setup | 10.57% | |
| Volume Surge | Other | 10.57% | |
| Calm After Storm | Range Contraction | 10.57% | |
| Narrow Range Bar | Range Contraction | 10.57% |
| Alert | Time |
|---|---|
| Up 10% | about 18 hours ago |
| 3x Volume Pace | about 18 hours ago |
| 2x Volume Pace | about 18 hours ago |
| 1.5x Volume Pace | about 18 hours ago |
| Rose Above Previous Day's High | about 19 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.
Keywords: Biotechnology Biopharmaceutical Diseases Pharmacy Rare Diseases Cell Therapy Gene Therapy Applied Genetics Stargardt Disease
Classification
Keywords: Biotechnology Biopharmaceutical Diseases Pharmacy Rare Diseases Cell Therapy Gene Therapy Applied Genetics Stargardt Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8 |
| 52 Week Low | 2.252 |
| Average Volume | 2,742 |
| 200-Day Moving Average | 4.85 |
| 50-Day Moving Average | 7.13 |
| 20-Day Moving Average | 6.53 |
| 10-Day Moving Average | 5.54 |
| Average True Range | 0.59 |
| RSI (14) | 29.58 |
| ADX | 23.68 |
| +DI | 23.04 |
| -DI | 56.04 |
| Chandelier Exit (Long, 3 ATRs) | 6.61 |
| Chandelier Exit (Short, 3 ATRs) | 4.89 |
| Upper Bollinger Bands | 10.27 |
| Lower Bollinger Band | 2.80 |
| Percent B (%b) | 0.1 |
| BandWidth | 114.38 |
| MACD Line | -1.00 |
| MACD Signal Line | -0.48 |
| MACD Histogram | -0.5146 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.29 | ||||
| Resistance 3 (R3) | 4.28 | 4.02 | 4.17 | ||
| Resistance 2 (R2) | 4.02 | 3.84 | 4.03 | 4.13 | |
| Resistance 1 (R1) | 3.80 | 3.73 | 3.91 | 3.81 | 4.09 |
| Pivot Point | 3.54 | 3.54 | 3.60 | 3.55 | 3.54 |
| Support 1 (S1) | 3.32 | 3.36 | 3.43 | 3.33 | 3.05 |
| Support 2 (S2) | 3.06 | 3.25 | 3.07 | 3.01 | |
| Support 3 (S3) | 2.84 | 3.06 | 2.97 | ||
| Support 4 (S4) | 2.85 |
